Literature DB >> 34880496

Non-genetic determinants of malignant clonal fitness at single-cell resolution.

Katie A Fennell1,2, Dane Vassiliadis1,2, Enid Y N Lam1,2, Luciano G Martelotto3, Jesse J Balic1, Sebastian Hollizeck1,2, Tom S Weber4,5, Timothy Semple1,3, Qing Wang6, Denise C Miles4,5, Laura MacPherson1,2, Yih-Chih Chan1,2, Andrew A Guirguis1,2, Lev M Kats1,2, Emily S Wong6,7, Sarah-Jane Dawson1,2,3, Shalin H Naik4,5, Mark A Dawson8,9,10.   

Abstract

All cancers emerge after a period of clonal selection and subsequent clonal expansion. Although the evolutionary principles imparted by genetic intratumour heterogeneity are becoming increasingly clear1, little is known about the non-genetic mechanisms that contribute to intratumour heterogeneity and malignant clonal fitness2. Here, using single-cell profiling and lineage tracing (SPLINTR)-an expressed barcoding strategy-we trace isogenic clones in three clinically relevant mouse models of acute myeloid leukaemia. We find that malignant clonal dominance is a cell-intrinsic and heritable property that is facilitated by the repression of antigen presentation and increased expression of the secretory leukocyte peptidase inhibitor gene (Slpi), which we genetically validate as a regulator of acute myeloid leukaemia. Increased transcriptional heterogeneity is a feature that enables clonal fitness in diverse tissues and immune microenvironments and in the context of clonal competition between genetically distinct clones. Similar to haematopoietic stem cells3, leukaemia stem cells (LSCs) display heritable clone-intrinsic properties of high, and low clonal output that contribute to the overall tumour mass. We demonstrate that LSC clonal output dictates sensitivity to chemotherapy and, although high- and low-output clones adapt differently to therapeutic pressure, they coordinately emerge from minimal residual disease with increased expression of the LSC program. Together, these data provide fundamental insights into the non-genetic transcriptional processes that underpin malignant clonal fitness and may inform future therapeutic strategies.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34880496     DOI: 10.1038/s41586-021-04206-7

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  41 in total

1.  When one mutation is all it takes.

Authors:  Mel Greaves
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Authors:  A V Krivtsov; M E Figueroa; A U Sinha; M C Stubbs; Z Feng; P J M Valk; R Delwel; K Döhner; L Bullinger; A L Kung; A M Melnick; S A Armstrong
Journal:  Leukemia       Date:  2012-12-13       Impact factor: 11.528

3.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia.

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Cancer Cell       Date:  2006-10       Impact factor: 31.743

4.  DiSNE Movie Visualization and Assessment of Clonal Kinetics Reveal Multiple Trajectories of Dendritic Cell Development.

Authors:  Dawn S Lin; Andrey Kan; Jerry Gao; Edmund J Crampin; Philip D Hodgkin; Shalin H Naik
Journal:  Cell Rep       Date:  2018-03-06       Impact factor: 9.423

Review 5.  Non-genetic mechanisms of therapeutic resistance in cancer.

Authors:  Jean-Christophe Marine; Sarah-Jane Dawson; Mark A Dawson
Journal:  Nat Rev Cancer       Date:  2020-10-08       Impact factor: 60.716

6.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

Review 7.  Cells of origin in cancer.

Authors:  Jane E Visvader
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

Review 8.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

Review 9.  Resolving genetic heterogeneity in cancer.

Authors:  Samra Turajlic; Andrea Sottoriva; Trevor Graham; Charles Swanton
Journal:  Nat Rev Genet       Date:  2019-07       Impact factor: 53.242

10.  Single-cell lineage tracing unveils a role for TCF15 in haematopoiesis.

Authors:  Alejo E Rodriguez-Fraticelli; Caleb Weinreb; Shou-Wen Wang; Rosa P Migueles; Maja Jankovic; Marc Usart; Allon M Klein; Sally Lowell; Fernando D Camargo
Journal:  Nature       Date:  2020-07-15       Impact factor: 49.962

View more
  6 in total

1.  Beyond genetics for cancer evolution.

Authors:  Darren J Burgess
Journal:  Nat Rev Genet       Date:  2022-02       Impact factor: 53.242

Review 2.  Untangling the web of intratumour heterogeneity.

Authors:  Zheqi Li; Marco Seehawer; Kornelia Polyak
Journal:  Nat Cell Biol       Date:  2022-08-08       Impact factor: 28.213

Review 3.  Mastering the use of cellular barcoding to explore cancer heterogeneity.

Authors:  Antonin Serrano; Jean Berthelet; Shalin H Naik; Delphine Merino
Journal:  Nat Rev Cancer       Date:  2022-08-18       Impact factor: 69.800

Review 4.  The expanding vistas of spatial transcriptomics.

Authors:  Luyi Tian; Fei Chen; Evan Z Macosko
Journal:  Nat Biotechnol       Date:  2022-10-03       Impact factor: 68.164

Review 5.  Killing SCLC: insights into how to target a shapeshifting tumor.

Authors:  Kate D Sutherland; Abbie S Ireland; Trudy G Oliver
Journal:  Genes Dev       Date:  2022-03-01       Impact factor: 11.361

6.  Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care.

Authors:  Shi-Ming Tu; Charles C Guo; Diana S-L Chow; Niki M Zacharias
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.